Nisa Investment Advisors LLC Sells 1,770 Shares of Guardant Health, Inc. (NASDAQ:GH)

Nisa Investment Advisors LLC lessened its holdings in Guardant Health, Inc. (NASDAQ:GH) by 51.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,680 shares of the company’s stock after selling 1,770 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Guardant Health were worth $45,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Captrust Financial Advisors raised its position in Guardant Health by 33.2% during the second quarter. Captrust Financial Advisors now owns 1,087 shares of the company’s stock worth $44,000 after acquiring an additional 271 shares in the last quarter. Baird Financial Group Inc. raised its position in Guardant Health by 2.1% during the third quarter. Baird Financial Group Inc. now owns 14,580 shares of the company’s stock worth $785,000 after acquiring an additional 296 shares in the last quarter. Public Employees Retirement System of Ohio raised its position in Guardant Health by 0.8% during the third quarter. Public Employees Retirement System of Ohio now owns 48,907 shares of the company’s stock worth $2,633,000 after acquiring an additional 385 shares in the last quarter. Oppenheimer Asset Management Inc. raised its position in Guardant Health by 2.8% during the third quarter. Oppenheimer Asset Management Inc. now owns 16,854 shares of the company’s stock worth $500,000 after acquiring an additional 453 shares in the last quarter. Finally, Amalgamated Bank raised its position in Guardant Health by 3.2% during the third quarter. Amalgamated Bank now owns 17,058 shares of the company’s stock worth $506,000 after acquiring an additional 521 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on GH. Piper Sandler dropped their price target on shares of Guardant Health from $40.00 to $30.00 and set an “overweight” rating on the stock in a research report on Monday, February 26th. Guggenheim reaffirmed a “neutral” rating on shares of Guardant Health in a research report on Friday, April 5th. JPMorgan Chase & Co. dropped their price target on shares of Guardant Health from $60.00 to $45.00 and set an “overweight” rating on the stock in a research report on Friday, February 23rd. Canaccord Genuity Group dropped their price objective on shares of Guardant Health from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Friday, February 23rd. Finally, The Goldman Sachs Group dropped their price objective on shares of Guardant Health from $32.00 to $28.00 and set a “buy” rating on the stock in a research report on Monday, April 15th. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $40.40.

Guardant Health Trading Down 3.6 %

GH stock opened at $16.07 on Monday. The company has a debt-to-equity ratio of 7.18, a quick ratio of 6.24 and a current ratio of 6.54. The company’s 50-day simple moving average is $19.21 and its 200 day simple moving average is $23.19. Guardant Health, Inc. has a 52 week low of $15.81 and a 52 week high of $41.06. The company has a market capitalization of $1.96 billion, a PE ratio of -3.75 and a beta of 0.87.

Guardant Health (NASDAQ:GH) last released its quarterly earnings results on Thursday, February 22nd. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($0.93) by ($0.65). Guardant Health had a negative net margin of 85.02% and a negative return on equity of 301.94%. The business had revenue of $155.05 million during the quarter, compared to analyst estimates of $151.71 million. As a group, sell-side analysts anticipate that Guardant Health, Inc. will post -3.49 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Kumud Kalia acquired 2,187 shares of Guardant Health stock in a transaction on Monday, March 18th. The shares were purchased at an average cost of $17.82 per share, for a total transaction of $38,972.34. Following the completion of the purchase, the insider now directly owns 12,722 shares of the company’s stock, valued at approximately $226,706.04. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 6.20% of the company’s stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.